These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38094526)

  • 21. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
    Watt M; McCrea C; Johal S; Posnett J; Nazir J
    Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes.
    Escudero-Sánchez R; Valencia-Alijo A; Cuéllar Tovar S; Merino-de Lucas E; García Fernández S; Gutiérrez-Rojas Á; Ramos-Martínez A; Salavert Lletí M; Castro Hernández I; Giner L; Cobo J
    Infection; 2021 Jun; 49(3):475-482. PubMed ID: 33417171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
    Okumura H; Ueyama M; Shoji S; English M
    J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
    van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
    Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
    Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of
    Alsoubani M; Chow JK; Rodday AM; Kent D; Snydman DR
    Open Forum Infect Dis; 2024 Jan; 11(1):ofad622. PubMed ID: 38204563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin.
    Sambol SP; Skinner AM; Serna-Perez F; Owen B; Gerding DN; Johnson S
    Microbiol Spectr; 2023 Mar; 11(2):e0051723. PubMed ID: 36975811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
    Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
    Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
    J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
    Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.
    Prohaska L; Mahmoudjafari Z; Shune L; Singh A; Lin T; Abhyankar S; Ganguly S; Grauer D; McGuirk J; Clough L
    Hematol Oncol Stem Cell Ther; 2018 Dec; 11(4):233-240. PubMed ID: 29928848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
    Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
    Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
    Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
    J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
    Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
    Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
    Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada.
    Wagner M; Lavoie L; Goetghebeur M
    Can J Infect Dis Med Microbiol; 2014 Mar; 25(2):87-94. PubMed ID: 24855476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.